ArticleJournal of investigative medicine high impact case reports

Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.

Maria G Fencer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.